NEW YORK, Sept. 18, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has received an additional $20 million from the National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH), to accelerate development of ST-246 for a therapeutic indication.
